XBiotech Inc. (XBIT)
NASDAQ: XBIT · Real-Time Price · USD
2.150
-0.020 (-0.92%)
Sep 28, 2026, 1:38 PM EDT - Market open
XBiotech Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
87
Market Cap
65.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 4.01M | -14.38M | -78.20% |
| Dec 31, 2021 | 18.39M | -25.60M | -58.19% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Champions Oncology | 60.66M |
| Gossamer Bio | 53.29M |
| MindWalk Holdings | 11.57M |
| Alps Group | 3.74M |
| Connect Biopharma Holdings | 2.95M |
| Alterity Therapeutics | 2.50M |
| Hyperion DeFi | 1.40M |
XBIT News
- 3 months ago - XBiotech to enroll patients in vilamakitug trial following FDA review - TheFly
- 3 months ago - XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - GlobeNewsWire
- 1 year ago - XBiotech trading resumes - TheFly
- 1 year ago - XBiotech pauses rheumatology program - TheFly
- 1 year ago - XBiotech trading halted, news pending - TheFly
- 1 year ago - XBiotech Pauses Rheumatology program - GlobeNewsWire
- 2 years ago - XBiotech trading resumes - TheFly
- 2 years ago - XBiotech announces data from Phase 1/2 1-BETTER study - TheFly